Background. The 2016-2017 influenza season in Israel was dominated by the circulation of influenza A(H3N2). Influenza vaccine is recommended for the entire population in Israel aged >6 months. The inactivated influenza vaccine was chosen for use this season.
Vaccination is the primary approach recommended to prevent influenza [1] . Ongoing genetic and antigenic changes among influenza viruses require continuing analyses of the circulating viruses [2] to determine influenza vaccine composition each year [3] . In recent years, influenza vaccine effectiveness (VE) studies have been conducted by various groups [4] . These studies demonstrated that influenza VE estimates can vary substantially, by season [5] , type/subtype [4] , and geographic location [4] .
Israel is a country of 8.7 million, located in the western part of Asia, adjacent to the southeastern coast of the Mediterranean Sea. Influenza activity in Israel is seasonal, taking place generally from December through March [6] in patterns comparable to those of Western Europe.
Israel's Ministry of Health endorses influenza vaccination for the whole population aged >6 months [7] . The influenza vaccines are administered through outpatient clinics of 4 healthcare services, with the inactivated influenza vaccines offered free of charge. Following the controversy regarding the effectiveness of live attenuated influenza vaccine in the 2015-2016 season [8, 9] , the inactivated influenza vaccine (trivalent or quadrivalent) was selected by the Israel Ministry of Health to be the vaccine of choice for the 2016-2017 season.
An outpatient sentinel influenza surveillance system was established in Israel 20 years ago and consists of primary care clinics located in all 7 districts of Israel and staffed by family physicians, pediatricians, and internists. During the 2016-2017 influenza season, 26 sentinel clinics took part in influenza surveillance.
The 2016-2017 influenza season in Israel started early and peaked in the beginning of January 2017, demonstrating moderate intensity in the community and marked by the dominance of influenza A(H3N2) [10] .
In this study, we estimated the 2016-2017 VE against laboratory-confirmed influenza in patients with influenza-like illness (ILI) attending the primary care sentinel clinics in Israel, using the test-negative design. We applied a novel analysis to better understand age-specific VE estimates during this season.
METHODS

Study Design and Population
VE against laboratory-confirmed influenza was estimated using the test-negative design [11, 12] and calculated as (1 -odds ratio) × 100, expressed as a percentage. The study period lasted from 2 October 2016 until 18 March 2017 (the influenza surveillance season), and was carried out in 26 outpatient sentinel clinics throughout Israel. Combined nasal-throat samples [13] were obtained from patients aged ≥6 months who met the following case definition of ILI: a temperature of ≥37.8°C, together with ≥1 of the following symptoms: coryza, cough, sore throat, and muscle ache [14] . Discretion has been given to providers to include other symptoms or signs deemed relevant. The combined nasal-throat swab kits were supplied by the Israel Central Virology Laboratory. Each clinic was asked to send up to 10 samples per week.
A questionnaire was completed for each sample gathering the following information: date of birth, sex, date of symptom onset, date of sample collection, the presence of chronic medical conditions, 2016-2017 influenza vaccination status, date of vaccination, and type of vaccine used. For children <9 years of age, the receipt of a second vaccine dose, if indicated (for those receiving the influenza vaccine for the first time), and the date of the second dose were also recorded.
An individual was defined as vaccinated if the 2016-2017 influenza vaccine was received ≥14 days prior to the onset of illness. Among children aged 6 months to 9 years receiving the influenza vaccine for the first time, only those who received 2 doses, with the second dose administered ≥14 days prior to onset of illness, were considered vaccinated. Samples obtained >7 days after the beginning of symptoms and <14 days after vaccination were excluded from the analysis.
VE was estimated only for influenza A(H3N2) due to the dominance of this subtype in the population during the 2016-2017 season.
Laboratory Methods
The combined nasal-throat samples obtained from sentinel ILI patients were transported weekly, in cooling containers, to the Israel Central Virology Laboratory, and tested for influenza A and B viruses as well as the subtype by real-time polymerase chain reaction as previously described [15] [16] [17] .
Nucleotide sequencing of the hemagglutinin (HA) gene from a subset of influenza A(H3N2) viruses circulating in Israel during the 2016-2017 season was performed as described elsewhere [17, 18] .
Statistical Analysis
Demographic characteristics were compared by means of the Pearson χ 2 test. The odds ratios for crude VE calculation and 95%
confidence intervals (CIs) were calculated utilizing a univariate logistic regression model. Adjustment for age group, sex, calendar month of sample collection, days from disease onset to swab, and influenza underlying chronic conditions was performed using a multivariable logistic regression model. VE was estimated for the entire study group and for specific age groups, for the entire season and for each week of the season. The VE estimates for each week included all cases and controls recruited by that week.
To gain a more detailed insight into VE at different ages, we developed a dynamic method of VE calculation. Dynamic VE is a nondiscrete stratification and visualization method for calculating VE for a subgroup of the data according to certain variable(s). VE was calculated for each 15-year window starting at the first year of age and moving gradually by 1 year.
We applied locally weighted scatterplot smoothing (LOWESS) [19] to the dynamic VE data, to visualize more clearly the trend of VE through the various ages and to better understand the relationship between VE and age.
We also applied cubic spline function to the adjusted VE data with knots placed at discrete 15-year age intervals [5, 19, 20] . This function has commonly been used to demonstrate changes in VE along a spectrum of variables [5, 20] . In this study, we used this function to demonstrate the changes in VE along the age spectrum in comparison to the dynamic VE.
Statistical analyses were carried out using SAS version 9.1.3 (SAS Institute, Cary, North Carolina) and R version 3.4.0 (R Foundation for Statistical Computing, Vienna, Austria) software.
Ethical Considerations
Sentinel ILI surveillance in Israel, inclusive of the viral detection component, is performed in accordance with the Public Health Ordinance enacted in Israel and does not necessitate informed consent.
RESULTS
Seasonality and Virus Circulation
Based on weekly rates of outpatient physician visits due to ILI per 10 000 Maccabi Healthcare Services members, the 2016-2017 season coincided with the epidemic threshold on epidemiologic week 49 ( Figure 1 
Vaccine Effectiveness
Due to clear dominance of influenza A(H3N2) in the 2016-2017 season, we estimated VE against this subtype only. Of the 1267 samples obtained, 179 samples were excluded because they did not meet the evaluation inclusion criteria (Figure 3 ). The characteristics of cases and controls included in the evaluation are shown in Table 1 The adjusted end-of-season VE against laboratory-confirmed influenza A(H3N2) in sentinel ILI patients for the 2016-2017 season for all ages was 29.0% (95% CI, .3%-49.5%; Table 2 ). Age group-specific adjusted VE was 69.2% (95% CI, 19.4%-88.3%) for children aged 5-17 years and 58.8% (95% CI, .8%-82.9%) for adults aged 45-64 years (Table 2 ). Adjusted VE estimates for the other age groups were lower, particularly for those aged ≥65 years, and were not statistically significant ( Table 2) .
The dynamic adjusted VE estimates are presented in Figure 4 . The highest VE estimates were observed among individuals aged 0.5-20 and 44-61 years ( Figure 4A ). Within the age range 0.5-20 years, the VE estimate of each 15- Figure 4A ). The lowest VE estimates (of <25%) were observed for the ages 20-49 years and ≥53 years. The low VE of the those aged 20-49 years corresponded with low vaccination rates of ≤10%, while the low VE among individuals aged ≥53 years occurred in the presence of substantially higher vaccination rates ( Figure 4A) . Figure 4B demonstrates the application of LOWESS to the data presented in Figure 4A . The application of LOWESS enables a clearer visualization of the trend of VE over the various ages and allows a better understanding of the relationship between VE and age. Figure 4C demonstrates the results of cubic spline function applied to the adjusted VE estimates, with knots at discrete 15-year age intervals. As shown, the dynamic VE (without and with LOWESS) reveals more detailed information of VE estimates at different ages compared with the cubic spline function.
Weekly VE Estimates
Adjusted weekly VE estimates for all ages and for individuals <65 years of age are demonstrated in Figure 5 . The adjusted VE point values were above zero in all the weeks presented in Figure 5 , and the 95% CIs generally narrowed with season progression ( Figure 5A and 5B). The weekly adjusted VE for individuals <65 years of age were higher than the adjusted VE for all ages from week 50 onward ( Figure 5B ), and were statistically significant from week 51 onward ( Figure 5B ). For individuals of all ages, the weekly adjusted VE estimates were statistically significant only on weeks 52, and borderline statistically significant on weeks 6, 10, and 11 ( Figure 5A ).
DISCUSSION
The 2016-2017 influenza season in Israel started early and was characterized by marked dominance of the influenza A(H3N2) subtype. The overall end-of-season adjusted VE against laboratory-confirmed influenza A(H3N2) in sentinel ILI patients was in the moderate-to-low range, with the age groups 5-17 years and 45-64 years demonstrating the highest VE ( Table 2) .
The relatively high VE among children 5-17 years old, coupled with the fact that children are thought to be instrumental in propagating respiratory pathogens [22, 23] , strongly supports vaccinating children against influenza. In this regard, a recent study demonstrated that influenza vaccination was associated with decreased mortality among children with laboratory-confirmed influenza [24] . Furthermore, several studies suggested that vaccination of children against influenza confers indirect protection in certain settings such as closely connected communities [25] and households [26, 27] .
The low VE with wide CI in children aged 0.5-4 years should be interpreted with caution. Substantial differences in social exposure and behaviors exist among children of different ages within this age group. Specifically, the older children within the 0.5-to 4-years age group are more likely to attend day care and have a wider social circle compared with the younger children of this age group [22] . As a result, they are more likely to contract disease from individuals outside their family. Thus, VE of older children in the youngest age group may resemble VE results observed for the 5-to 17-years age group. A larger number of children in the 0.5-to 4-years age group is necessary to examine this phenomenon.
The relatively high VE among adults aged 45-64 years stands in sharp contrast to the low VE found among adults aged 18-44 years. The lower influenza vaccination rate among those aged 18-44 years (Table 2 ) may have led to reduced precision of its VE estimate.
The adjusted VE was particularly low in those aged ≥65 years. These results are particularly interesting in view of the substantially higher vaccination rates in this age group, among cases and controls, compared with the other age groups (Table 2 and Figure 4A ).
Our end-of season influenza A(H3N2) VE estimate for all ages is consistent with that of the United States Flu VE network (34%, statistically significant) [28] . Furthermore, similar to Israel, the US Flu VE Network age-specific VE against influenza A(H3N2) demonstrated low VE without statistical significance in the age groups 18-49 and ≥65 years, while showing higher and statistically significant VE in the other age groups [28] . The low VE estimates we found in those aged ≥65 years were also consistent with the findings of other studies [4, [29] [30] [31] .
These low VE estimates in those aged ≥65 years are of concern due to the fact that individuals in this age group are at increased risk of developing complications and are thus in greater need of vaccine-induced protection.
Estimating VE for predetermined age groups is informative; however, it may not provide sufficient information due to the discrete nature of these age groups. Furthermore, some age groups may not be sufficiently large to allow an accurate VE estimation. To address these issues, we developed a dynamic VE estimation method. This method is described and used here for the first time. The dynamic VE method appears useful in providing details about VE changes along smaller age intervals, compared with the age-group VE presented in Table 2 . A method that has commonly been used to demonstrate changes in VE along a spectrum of variables, such as age, is the cubic spline function [5, 20] . By comparing the dynamic VE to the cubic spline function of the adjusted VE estimates ( Figure 4A -C), we were able to show that the dynamic VE method reveals more detailed VE estimates at various ages. Abbreviations: CI, confidence interval; VE, vaccine effectiveness. a Adjustment for age as a categorical variable (age categories: 0.5-4, 5-17, 18-44, 45-64, and ≥65 years), sex, calendar month of sample collection, days from disease onset to swab, and influenza underlying chronic conditions was done as outlined in the Methods. b Adjusted for age (as a continuous variable) sex, calendar month of sample collection, days from disease onset to swab, and influenza underlying chronic conditions.
Our 2016-2017 analysis demonstrates differences in VE among different age groups, suggesting that the overall modest end-of-season VE estimate may not to be useful by itself. Our data support the analysis of VE according to age, including the use of dynamic VE analysis, while considering additional factors such as influenza vaccination rates.
Most VE studies provide end-of-season VE, and some provide midseason VE. However, a week-by-week account of adjusted VE can be very useful for within-season decision making, such as recommendation for antiviral use. Our weekly analysis indicated rather early that the influenza vaccine was less effective in individuals aged ≥65 years throughout the season.
The variability in amino acid substitutions observed in Israel during the 2016-2017 season [17] is consistent with the variability shown in studies originating from Canada, InfluenzaMonitoring Vaccine Effectiveness network (I-MOVE), and the United Kingdom [30, 32, 33] . However, the size of our study did not allow VE estimation against influenza A(H3N2) based on genetic group.
The 2016-2017 end-of-season VE results against influenza A(H3N2) from Israel and midseason VE estimates from Northern Hemisphere countries [30, 34] are higher than those obtained for the 2014-2015 season, when the influenza A(H3N2) vaccine component was found to confer little or no protection against influenza in community settings [11, 35, 36] . Whereas [17] .
Selection of influenza A(H3N2) vaccine components is challenging as mutations occur in this influenza virus subtype more frequently compared with influenza A(H1N1) or influenza B [37] . In fact, a recent meta-analysis demonstrated that VE estimates against influenza A(H3N2) tend to be lower than VE against influenza A(H1N1) or influenza B [4] .
The divergence of influenza A(H3N2) HA amino acid substitutions during the 2016-2017 season, and the inability to predict which amino acid substitution group will become dominant globally, suggests a need for a continuous evaluation of the different genetic groups, in terms of amino acid substitutions, antigenic comparability, global spread, and their effect on VE.
Our study has several limitations. In recent years, various studies examined the effect of prior influenza vaccinations on influenza VE in community settings [38] [39] [40] [41] . A 2016-2017 midseason VE evaluation from northern Spain demonstrated that VE results varied based on the history of prior influenza vaccinations, with history of ≥3 prior influenza vaccine doses affecting negatively the current year VE [42] . A recent systematic review and meta-analysis did not find evidence that influenza vaccination in the prior season negatively affected current season VE [43] . Unfortunately, history of prior influenza vaccination among individuals included in our VE analysis was not available for the current study.
The use of statins was recently reported to be associated with reduced VE against influenza [44, 45] and low hemagglutination inhibition antibody titers following influenza vaccination [45, 46] . Information regarding medication use among the study individuals was not available for the current study.
A relatively small number of individuals aged ≥65 years were included in our study, as well as in other VE studies [8, 47, 48] . Furthermore, based on health management organization databases in Israel, relatively small numbers of individuals aged ≥65 years with ILI have been observed in primary care clinics during the influenza seasons [6, 49] . These findings raise the possibility that many individuals belonging to this age group may suffer rapid clinical deterioration upon developing respiratory symptoms, requiring them to obtain prompt hospital care rather than visit their primary physician. The small numbers of individuals in the ≥65 age group from our study may make the VE results of this age group difficult to generalize.
We are continuing our efforts to expand our capacity for accurate and timely analysis of VE estimates. These efforts are particularly important due to the unique geographic location, climate conditions, and diverse population of Israel.
Notes
